{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T23:47:59Z","timestamp":1789084079629,"version":"build-2803163510"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100020964","name":"Fusion Oriented REsearch for disruptive Science and Technology","doi-asserted-by":"crossref","award":["JPMJFR2065"],"award-info":[{"award-number":["JPMJFR2065"]}],"id":[{"id":"10.13039\/501100020964","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100015650","name":"Canon Medical Systems Corporation","doi-asserted-by":"crossref","award":["S22-0047"],"award-info":[{"award-number":["S22-0047"]}],"id":[{"id":"10.13039\/100015650","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>An immunosuppressive tumor microenvironment that facilitates cancer progression is an important challenge in combating the disease. The CCL2\u2013CCR2 axis is a primary facilitator in this process, facilitating the recruitment of CCR2-positive myeloid cells, including M-MDSCs and TAMs, to tumor and metastatic locations. CCR2 is also expressed on tumor cells and regulatory T cells, further enhancing cancer cell motility and immune suppression. Inhibition of this system through genetic deletion or small-molecule inhibitors significantly reduces primary tumor and metastasis in preclinical models, highlighting CCR2 as a promising therapeutic target. Although several CCR2 inhibitors have entered clinical trials, differences in their potency and the limited predictability of murine models have hampered clinical translation. The current work by Sugiyama et\u00a0al. carefully evaluated 10 human CCR2 antagonists, identifying MK0812 as the most effective inhibitor. Using human CCR2B knock-in mice, they established a practical platform for evaluating CCR2-targeted drugs with direct relevance to human cancer therapy, highlighting the importance of humanized models for translational immuno-oncology.<\/jats:p>","DOI":"10.1093\/jb\/mvag009","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T11:38:58Z","timestamp":1775907538000},"page":"375-378","source":"Crossref","is-referenced-by-count":2,"title":["Targeting the CCL2\u2013CCR2 axis in cancer: insights into in vitro screening and humanized mice"],"prefix":"10.1093","volume":"179","author":[{"given":"Yanjun","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Molecular Biology, Graduate School of Medicine, Nagoya University , 65 Tsurumai-cho, Showa-ku, Nagoya 466-8560 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Midori","family":"Shimada","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology, Graduate School of Medicine, Nagoya University , 65 Tsurumai-cho, Showa-ku, Nagoya 466-8560 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"2026052601013919900_ref1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"2026052601013919900_ref2","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70557","article-title":"Immune cell profiling reveals a common pattern in Premetastatic niche formation across various cancer types","volume":"14","author":"Sugiyama","year":"2025","journal-title":"Cancer Med"},{"key":"2026052601013919900_ref3","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3389\/fimmu.2019.00172","article-title":"MDSCs: key criminals of tumor pre-metastatic niche formation","volume":"10","author":"Wang","year":"2019","journal-title":"Front. Immunol."},{"key":"2026052601013919900_ref4","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1111\/cas.14075","article-title":"Potentials of C-C motif chemokine 2-C-C chemokine receptor type 2 blockers including propagermanium as anticancer agents","volume":"110","author":"Yumimoto","year":"2019","journal-title":"Cancer Sci"},{"key":"2026052601013919900_ref5","doi-asserted-by":"crossref","first-page":"6483","DOI":"10.1158\/0008-5472.CAN-16-0984","article-title":"CCR2 influences T regulatory cell migration to tumors and serves as a biomarker of cyclophosphamide sensitivity","volume":"76","author":"Loyher","year":"2016","journal-title":"Cancer Res"},{"key":"2026052601013919900_ref6","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/jb\/mvad086","article-title":"Identification of effective CCR2 inhibitors for cancer therapy using humanized mice","volume":"175","author":"Sugiyama","year":"2024","journal-title":"J. Biochem"},{"key":"2026052601013919900_ref7","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1158\/0008-5472.CAN-12-2731","article-title":"Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses","volume":"73","author":"Mitchem","year":"2013","journal-title":"Cancer Res"},{"key":"2026052601013919900_ref8","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1172\/JCI78782","article-title":"F-box protein FBXW7 inhibits cancer metastasis in a non-cell-autonomous manner","volume":"125","author":"Yumimoto","year":"2015","journal-title":"J. Clin. Invest"},{"key":"2026052601013919900_ref9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.771210","article-title":"Targeting the CCL2\/CCR2 axis in cancer immunotherapy: one stone, three birds?","volume":"12","author":"Fei","year":"2021","journal-title":"Front. Immunol"},{"key":"2026052601013919900_ref10","article-title":"Role of the CCL2-CCR2 axis in cardiovascular disease: pathogenesis and clinical implications","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol"},{"key":"2026052601013919900_ref11","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ajpath.2024.12.007","article-title":"Chemokine (C-C motif) ligand 2\/CCR2\/extracellular signal-regulated kinase signal induced through cancer cell-macrophage interaction contributes to hepatocellular carcinoma progression","volume":"195","author":"Ishihara","year":"2025","journal-title":"Am. J. Pathol"},{"key":"2026052601013919900_ref12","doi-asserted-by":"crossref","first-page":"36593","DOI":"10.1074\/jbc.M112.365999","article-title":"CCL2\/CCR2 chemokine signaling coordinates survival and motility of breast cancer cells through Smad3 protein- and p42\/44 mitogen-activated protein kinase (MAPK)-dependent mechanisms","volume":"287","author":"Fang","year":"2012","journal-title":"J. Biol. Chem"},{"key":"2026052601013919900_ref13","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/ndt\/gfs555","article-title":"Blockade of CCL2\/CCR2 signalling ameliorates diabetic nephropathy in db\/db mice","volume":"28","author":"Seok","year":"2013","journal-title":"Nephrol. Dial. Transplant"},{"key":"2026052601013919900_ref14","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106314","article-title":"The role of chemokines and chemokine receptors in multiple sclerosis","volume":"83","author":"Cui","year":"2020","journal-title":"Int. Immunopharmacol"},{"key":"2026052601013919900_ref15","doi-asserted-by":"crossref","first-page":"28697","DOI":"10.18632\/oncotarget.7376","article-title":"Targeting the CCL2-CCR2 signaling axis in cancer metastasis","volume":"7","author":"Lim","year":"2016","journal-title":"Oncotarget"},{"key":"2026052601013919900_ref16","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S1470-2045(16)00078-4","article-title":"Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-Centre, open-label, dose-finding, non-randomised, phase 1b trial","volume":"17","author":"Nywening","year":"2016","journal-title":"Lancet Oncol"},{"key":"2026052601013919900_ref17","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.2217\/pgs.15.74","article-title":"Exploratory analysis of candidate germline gene polymorphisms in breast cancer patients treated with neoadjuvant anthracycline-containing chemotherapy and associations with febrile neutropenia","volume":"16","author":"Charehbili","year":"2015","journal-title":"Pharmacogenomics"},{"key":"2026052601013919900_ref18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2004.10.014","article-title":"Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo","volume":"106","author":"Jonker","year":"2005","journal-title":"Pharmacol. Ther"},{"key":"2026052601013919900_ref19","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/ddr.10044","article-title":"Targeted replacement of rodent CCR2 with the human orthologue CCR2B: a mouse model for in vivo analysis of human target-selective small molecule MCP-1 receptor antagonists","volume":"55","author":"Prosser","year":"2002","journal-title":"Drug Dev. Res"}],"container-title":["The Journal of Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jb\/advance-article-pdf\/doi\/10.1093\/jb\/mvag009\/68079786\/mvag009.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jb\/article-pdf\/179\/6\/375\/68079786\/mvag009.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jb\/article-pdf\/179\/6\/375\/68079786\/mvag009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T05:01:46Z","timestamp":1779771706000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jb\/article\/179\/6\/375\/8653942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":19,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,4,14]]},"published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jb\/mvag009","relation":{},"ISSN":["0021-924X","1756-2651"],"issn-type":[{"value":"0021-924X","type":"print"},{"value":"1756-2651","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,4,14]]}}}